LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 3 | F01 | 72 | hr | 2543 | 967 | 5578 | 0.1733 | -0.5194 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 1 | G01 | 72 | hr | 2543 | 670 | 5578 | 0.1201 | -0.6172 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 2 | G01 | 72 | hr | 2543 | 840 | 5578 | 0.1506 | -0.5612 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 3 | G01 | 72 | hr | 2543 | 707 | 5578 | 0.1267 | -0.6051 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 1 | P13 | 72 | hr | 2543 | 2817 | 5578 | 0.5050 | 0.0901 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 2 | P13 | 72 | hr | 2543 | 3759 | 5578 | 0.6738 | 0.4005 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 3 | P13 | 72 | hr | 2543 | 3754 | 5578 | 0.6729 | 0.3988 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 1 | A07 | 72 | hr | 2543 | 2207 | 5578 | 0.3956 | -0.1109 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 2 | A07 | 72 | hr | 2543 | 1766 | 5578 | 0.3166 | -0.2562 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 3 | A07 | 72 | hr | 2543 | 2216 | 5578 | 0.3972 | -0.1079 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 1 | I07 | 72 | hr | 2543 | 5340 | 5578 | 0.9572 | 0.9214 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 2 | I07 | 72 | hr | 2543 | 5973 | 5578 | 1.0707 | 1.1299 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 3 | I07 | 72 | hr | 2543 | 5767 | 5578 | 1.0338 | 1.0620 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 1 | A19 | 72 | hr | 2543 | 1681 | 5578 | 0.3013 | -0.2842 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 2 | A19 | 72 | hr | 2543 | 1738 | 5578 | 0.3115 | -0.2654 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 3 | A19 | 72 | hr | 2543 | 1914 | 5578 | 0.3431 | -0.2074 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 1 | P07 | 72 | hr | 2543 | 2610 | 5578 | 0.4679 | 0.0219 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 2 | P07 | 72 | hr | 2543 | 2712 | 5578 | 0.4861 | 0.0555 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 3 | P07 | 72 | hr | 2543 | 3015 | 5578 | 0.5405 | 0.1554 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 1 | D01 | 72 | hr | 2543 | 2600 | 5578 | 0.4661 | 0.0186 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 2 | D01 | 72 | hr | 2543 | 2577 | 5578 | 0.4619 | 0.0111 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 2543 | 2443 | 5578 | 0.4379 | -0.0331 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 1 | I01 | 72 | hr | 2543 | 1065 | 5578 | 0.1909 | -0.4871 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 2 | I01 | 72 | hr | 2543 | 1533 | 5578 | 0.2748 | -0.3329 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 3 | I01 | 72 | hr | 2543 | 1462 | 5578 | 0.2621 | -0.3563 |